Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Optibrium Ltd
Optibrium Ltd
Activities:
Research & Development
Digital
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Optibrium launches a metabolism prediction software platform tailored to DMPK scientists
Semeta can be used for the prediction of Phase I and II metabolic routes, sites, products and liabilities in early drug discovery
Finance
Optibrium acquires 3D drug design specialist BioPharmics
Following the acquisition, BioPharmics’ Drs Ajay Jain (CEO) and Ann Cleves (Director of Applied Science) join the Optibrium team as VP in the newly-created BioPharmics Division
Finance
Optibrium receives further investment from Kester Capital
Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology
Finance
Optibrium appoints Prof Andy Black non-executive chair
Prior to his current roles, Black co-founded Kinapse, an international business providing expert advisory and implementation services to life science industries
Research & Development
Optibrium releases 3D design module for drug discovery software
This expansion is a result of a collaboration between BioPharmics and Optibrium
Finance
Optibrium and BioPharmics enter computational drug design collaboration
The Surflex eSim 3D module, planned for the 3rd quarter of 2021, will use BioPharmics’ 3D ligand-based design approaches
Drug Delivery
Optibrium launches AI software platform for drug discovery
It's the latest member of Optibrium's Augmented Chemistry platform of AI technologies
Subscribe now